Nyxoah SA - Ordinary Shares (NYXH)

On our desk, NYXH has been an interesting case study in divergence. While the Q4 2025 earnings release showed an EPS miss, the market has fixated squarely on the 121 percent year-over-year top-line expansion. Opening near $1.45 with a bullish technical posture, sentiment is tilting favorably among growth-oriented retail participants who are willing to overlook near-term earnings friction for scale.

From a quantitative standpoint, evaluating NYXH requires balancing explosive year-over-year growth metrics against structural profitability hurdles. The equity's ability to maintain upward momentum from its recent price levels will depend heavily on whether management can narrow the EPS gap while sustaining its aggressive revenue trajectory in upcoming quarters.

Watching the tape on Nyxoah SA, the risk profile remains tightly bound to its fundamental execution. Delivering triple-digit revenue growth is commendable for a medical technology firm, but the earnings shortfall signals that operational burn and bottom-line efficiency will remain under intense scrutiny as market conditions evolve through 2026.